Search Results

Susan G. Komen®, the world’s leading breast cancer organization, announced $10.05 million in research grants that aim to improve patient lives through better treatments for metastatic disease and advancements in precision medicine.

Susan G. Komen®, the world’s leading breast cancer organization, announced four new global leaders to serve on its Board of Directors.

Susan G. Komen®, the world’s leading breast cancer organization and Walgreens announced another milestone in the transformative five-year collaboration that has not only propelled groundbreaking research in breast cancer but has also significantly expanded access to essential breast health and breast cancer services, support and resources.

Susan G. Komen®, the world’s leading breast cancer organization, has launched the Stand for H.E.R. – A Health Equity Revolution Breast Cancer Impact Report.

Susan G. Komen ® , the world’s leading breast cancer organization, today announced the awarding of 49 new grants to researchers at 28 leading institutions in the U.S.

- Company listed in Research and Markets’ announcement and description of new research report on the U.S. Breast Cancer Screening and Diagnostic Market- - “U.S. breast cancer screening and diagnostic [device] market was valued at $1.55 billion in 2024 and is anticipated to reach $2.34 billion by the end of 2030, at a CAGR of 7.05% during the forecast period 2024-20301"- -Report supports Company’s regulatory strategy for IzoView Breast CT, reinforces high demand for new breast imaging modalities, strengthens the potential for rapid market adoption and significant market share -

Susan G. Komen®, the world’s leading breast cancer organization, has appointed nine world-renowned medical and research experts to serve as advisors to the organization.

-A screening indication for women with dense breast tissue adjunctive to 3D mammography increases the market size for annual IzoView scans by over 800%1 for initial approval and product launch- -Regulatory strategy responds to the “urgent call2" from the U.S. Preventative Services Task Force for solutions to finding breast cancers earlier in women with dense breast tissue- -Comprehensive filing includes patient acquisition and clinical study plans that validate a projected clinical study timeline of 2.5 years with an approximate cost of USD 3.5 million-

G1 Therapeutics on Monday reported Phase III study results showing its drug Cosela did not demonstrate a statistically significant effect in overall survival in triple-negative breast cancer patients.